Adriano Solidoro

  • Citations Per Year
Learn More
nosed at the Instituto Nacional de Enfermedades Neoplá.sicasof Peru between 1952 and 1964. Sixty-one of these (40.7%) were under 15 years of age. The proportion of cases in the 1st decade of life (30%) is much higher than that found in other reported series. The male/female ratio parallels that in all other reported series, both for patients under 15 years(More)
Cyclophosphamide was administered to 42 patients with acute lymphocytic leukemia (ALL) as a daily continuous iv infusion at a dose of 400 mg/m2/day x 5 days; the courses of treatment were repeated every 3 weeks. Of the 42 patients entered, 21 achieved a complete response, two achieved a partial response, 12 failed to respond, and seven were considered to(More)
The results of radiologic and endoscopic examinations and endoscopic biopsies of the stomach and duodenum in the staging of non-Hodgkin's lymphoma (NHL) were assessed in 147 patients. Radiologic results were positive for non-Hodgkin's lymphoma in 36 of 147 patients, with diagnosis of NHL from biopsy specimens of 16 of these 36 patients. Results of(More)
Twenty-one of 65 patients with gastric lymphoma have been treated with combination chemotherapy; 17 patients had chemotherapy as primary treatment, and 4 had it for residual disease after incomplete surgical resection. Three of these patients were in stage III and 18 were in stage IV of the disease, according to the TNM Staging Classification. CHOP-Bleo or(More)
AIM Topical vancomycin applied to the oropharynx has been shown to control carriage and lower airway infection due to methicillin-resistant Staphylococcus aureus (MRSA). We undertook a three-year prospective observational study to evaluate the effectiveness of two policies for topical vancomycin administration on oropharyngeal carriage and lower airway(More)
We have performed a phase II study to evaluate the activity and toxicity of ifosfamide and cisplatin as first-line treatment for advanced ovarian cancer. Patients were treated with cisplatin 100 mg/m2 on day 1 and ifosfamide 5 g/m2 in 18-hr continuous infusion on day 1 or 1.5 g/m2 bolus on days 1-5. Between August 1988 and March 1990, 30 women were entered(More)
Based on previous reports suggesting that an intravenous (i.v.) continuous infusion of alkylating agents produced a significant response rate in acute lymphoblastic leukemia (ALL), a phase I trial of ifosfamide/mesna (IFO/MES) was conducted in 11 adult patients with relapsed ALL. IFO/MES were administered as a 24-h i.v. continuous infusion in doses ranging(More)